JP7837873B2 - ヒト化抗TrkA抗体及びその使用 - Google Patents

ヒト化抗TrkA抗体及びその使用

Info

Publication number
JP7837873B2
JP7837873B2 JP2022555685A JP2022555685A JP7837873B2 JP 7837873 B2 JP7837873 B2 JP 7837873B2 JP 2022555685 A JP2022555685 A JP 2022555685A JP 2022555685 A JP2022555685 A JP 2022555685A JP 7837873 B2 JP7837873 B2 JP 7837873B2
Authority
JP
Japan
Prior art keywords
seq
trka
antibody
igg4
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022555685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549300A5 (cg-RX-API-DMAC7.html
JP2023549300A (ja
Inventor
ジヘン・レン
ジュンジ・ドン
ジュアンディ・ヘ
ケジュ・ワン
ジエリアン・ル
シュシャン・リン
リャン・リウ
シアン・リ
クオ・ジャン
ヤン・ジアン
シャオピン・リ
シャオフェン・チェン
ウェンジア・リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2023549300A publication Critical patent/JP2023549300A/ja
Publication of JP2023549300A5 publication Critical patent/JP2023549300A5/ja
Application granted granted Critical
Publication of JP7837873B2 publication Critical patent/JP7837873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
JP2022555685A 2020-11-20 2021-11-18 ヒト化抗TrkA抗体及びその使用 Active JP7837873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011307482.7 2020-11-20
CN202011307482 2020-11-20
PCT/CN2021/131343 WO2022105814A1 (en) 2020-11-20 2021-11-18 Humanized anti-trka antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023549300A JP2023549300A (ja) 2023-11-24
JP2023549300A5 JP2023549300A5 (cg-RX-API-DMAC7.html) 2024-10-28
JP7837873B2 true JP7837873B2 (ja) 2026-03-31

Family

ID=81595256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555685A Active JP7837873B2 (ja) 2020-11-20 2021-11-18 ヒト化抗TrkA抗体及びその使用

Country Status (7)

Country Link
US (1) US20230357411A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247852A4 (cg-RX-API-DMAC7.html)
JP (1) JP7837873B2 (cg-RX-API-DMAC7.html)
CN (1) CN114516917B (cg-RX-API-DMAC7.html)
AU (1) AU2021382828A1 (cg-RX-API-DMAC7.html)
TW (1) TWI880048B (cg-RX-API-DMAC7.html)
WO (1) WO2022105814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120360963B (zh) * 2025-04-23 2026-02-27 广州芬瑞生物科技有限公司 干细胞外泌体制备方法及该方法制备的外泌体在治疗男性勃起功能障碍中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501103A (ja) 1999-06-10 2003-01-14 アブジェニックス インク. 非同種スイッチ領域を介して、ヒト抗体の特定のアイソタイプを産生するためのトランスジェニック動物
JP2015520182A (ja) 2012-06-08 2015-07-16 グレンマーク ファーマシューティカルズ, エセ.アー. アミノ酸置換を有するヒト化抗TrkA抗体
US20160244529A1 (en) 2012-06-13 2016-08-25 Rottapharm Biotech S.R.L. Anti-trka antibodies, derivatives and uses thereof
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273115C1 (en) * 2000-06-29 2009-03-26 Quick Med Technologies, Inc. Cosmetic composition and method
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0905955A8 (pt) * 2008-02-04 2018-05-08 Lay Line Genomics Spa anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado
US9539324B2 (en) * 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US20170362327A1 (en) * 2015-04-24 2017-12-21 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
AU2020281378B2 (en) * 2019-05-30 2025-09-11 Sunshine Lake Pharma Co., Ltd. Anti-TrkA antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501103A (ja) 1999-06-10 2003-01-14 アブジェニックス インク. 非同種スイッチ領域を介して、ヒト抗体の特定のアイソタイプを産生するためのトランスジェニック動物
JP2015520182A (ja) 2012-06-08 2015-07-16 グレンマーク ファーマシューティカルズ, エセ.アー. アミノ酸置換を有するヒト化抗TrkA抗体
US20160244529A1 (en) 2012-06-13 2016-08-25 Rottapharm Biotech S.R.L. Anti-trka antibodies, derivatives and uses thereof
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Also Published As

Publication number Publication date
CN114516917A (zh) 2022-05-20
CN114516917B (zh) 2022-11-18
AU2021382828A1 (en) 2022-10-06
WO2022105814A1 (en) 2022-05-27
TWI880048B (zh) 2025-04-11
TW202227500A (zh) 2022-07-16
US20230357411A1 (en) 2023-11-09
EP4247852A1 (en) 2023-09-27
JP2023549300A (ja) 2023-11-24
EP4247852A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
EP3845561A1 (en) Anti-cd47 antibody and application thereof
CN101939337B (zh) 抗trka抗体及其衍生物
TWI908724B (zh) TrkA的抗體及其應用
EP4148068A1 (en) Anti-tigit antibody and preparation method and application thereof
KR20200139725A (ko) Her3 항원 결합 분자
CN111032688A (zh) 用于延长的血清半衰期的工程化抗体fc变体
EP3247728A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN111819201A (zh) Pd1结合剂
CN111788229A (zh) Csf1r结合剂
TWI880048B (zh) 人源化抗TrkA的抗體及其應用
JP7849148B2 (ja) 抗cd26抗体の奏効性バイオマーカー
WO2025241702A1 (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
WO2025241703A1 (zh) 高亲和力b7h7抗体或其抗原结合片段及其用途
WO2025256571A1 (zh) 靶向b7h7和cd3的双特异性抗体及其应用
KR20250124805A (ko) Cd24에 대한 항체 및 이의 용도
KR20230142838A (ko) 항-vegf 항체 및 이의 용도
CN115572330A (zh) 一种特异性抗体及其制备方法和应用
WO2026026847A1 (zh) 一种b7-h3特异性抗体及其抗肿瘤应用
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도
CN117715932A (zh) 一种cdc平台抗体
OA18848A (en) Anti - TRKA antibodies and derivatives thereof.
KR20120130478A (ko) TNF?α 특이적 항체 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260318

R150 Certificate of patent or registration of utility model

Ref document number: 7837873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150